Clinics in Dermatology
Volume 24, Issue 4 , Pages 237-246 , July 2006

Diabetes mellitus

References 

  1. Centers for Disease Control and Prevention . National diabetes fact sheet: national estimates on diabetes. http://www.cdc.gov/diabetes/pubs/estimates.htm#prev2005;
  2. Engelgau MM, et al. The evolving diabetes burden in the United States. Ann Intern Med. 2004;140:945–950
  3. Perez MI, Cohn SR. Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol. 1994;30:519–531
  4. Paron MG, Lambert PW. Cutaneous manifestations of diabetes mellitus. Prim Care. 2000;27:371–383
  5. Romano G, Moretti G, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract. 1998;39:101–106
  6. Stuart CA, Gilkison CR, et al. Acanthosis nigricans as a risk factor for non–insulin dependent diabetes mellitus. Clin Pediatr. 1998;37:73–80
  7. Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol. 2004;5:199–203
  8. Veysey E, Ratnavel R. Facial acanthosis nigricans associated with obesity. Am J Clin Dermatol. 2005;30:437–439
  9. Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab. 2003;88:5433–5437
  10. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929–1935
  11. Lobie PE, Breipohl W, Lincoln DT, Garcia-Aragon J, Waters MJ. Localization of the growth hormone receptor/binding protein in skin. J Endocrinol. 1990;126:467–471
  12. Stratakis CA, Mastorakos G, Mitsiades NS, Mitsiades CS, Chrousos GP. Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia. Pediatr Dermatol. 1998;15:253–258
  13. Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine. 2004;83:209–222
  14. Cruz P, Hud J. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol. 1992;98:82S
  15. Yeh JS, Munn SE, Plunkett TA, et al. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol. 2000;42(2 Pt 2):357–362
  16. Stals H, Vercammen C, Peeters C, Morren MA. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology. 1994;189:203–206
  17. Dunaif A, Green G, Pleps R. Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab. 1991;73:590–595
  18. Scheretz EF. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation. Arch Dermatol. 1988;24:1094–1096
  19. Jelinek JE. The skin and diabetes. Philadelphia: Lea & Febiger; 1986;
  20. Ferringer T, Miller F. Cutaneous manifestations of diabetes mellitus. Dermatol Clin. 2002;20:483–492
  21. Lithner F. Cutaneous reactions of the extremities of diabetic to local thermal trauma. Acta Med Scand. 1975;198:319
  22. Fisher ER, Danowski TS. Histologic, histochemical, and electron microscopic features of the shin spots of diabetes mellitus. Am J Clin Pathol. 1968;50:547–554
  23. Lowitt MH, Dover JS. Necrobiosis lipoidica. J Am Acad Dermatol. 1991;25:735
  24. Dwyer CM, Dick D. Ulceration in necrobiosis lipoidica: a case report and study. Clin Exp Dermatol. 1993;18:366
  25. Petzelbauer P, et al. Necrobiosis lipoidica: treatment with systemic corticosteroids. Br J Dermatol. 1992;126:542
  26. Iwasaki T, Kohoma T, et al. Diabetic scleredema and scleroderma-like changes in a patient with maturity onset type diabetes of the young people. Dermatology. 1994;188:228
  27. Kapoor A, Sibbitt WL. Contracture in diabetes mellitus: the syndrome of limited joint mobility. Semin Arthritis Rheum. 1989;18:168–180
  28. Seibold J. Digital sclerosis in children with insulin-dependent diabetes mellitus. Arthritis Rheum. 1982;25:1357–1361
  29. Libecco JF. Finger pebbles and diabetes: a case with broad involvement of dorsal fingers and hands. Acta Dermatol. 2001;137:510–511
  30. Fleischmajer R, Faludi G, Krol S. Scleredema and diabetes mellitus. Arch Dermatol. 1970;101:21–35
  31. Silbert C, Kleinman HK. Studies of cultured human fibroblasts in diabetes mellitus. Changes in heparan sulphate. Diabetes. 1979;28:61–64
  32. Forst T, Kann P, et al. Association between diabetic thick skin syndrome and neurological disorders in diabetes mellitus. Acta Diabetol. 1994;31:73–77
  33. Yosipovitch G, Yosipovitch Z, Karp M, Mukamel M. Trigger finger in young patients with insulin dependent diabetes. J Rheumatol. 1990;17:951–952
  34. Yosipovitch G, Loh KC, Hock OB. Medical pearls: scleroderma-like skin changes in patients with diabetes mellitus. J Am Acad Dermatol. 2003;48:109–111
  35. Glasoe WM, Allen MK, Ludewig PM, Saltzman CL. Dorsal mobility and first ray stiffness in patients with diabetes mellitus. Foot Ankle Int. 2004;25:550–555
  36. Samlaska CP, et al. Generalized perforating granuloma annulare. J Am Acad Dermatol. 1992;27:319
  37. Schleicher SM, Milstein HJ. Resolution of disseminated granuloma annulare following isotretinoin therapy. Cutis. 1985;1
  38. Setterfield J, Huilgol S, Black M. Generalised granuloma annulare successfully treated with PUVA. Clin Exp Dermatol. 1999;24:458
  39. Suzuki K, Ito Y, Nakamura S, Ochiai J, Aoki K. Relationship between serum carotenoids and hyperglycemia: a population-based cross-sectional study. J Epidemiol. 2002;12:357–366
  40. Lipsky BA, Baker PD, et al. Diabetic bullae: 12 cases of purportedly rare cutaneous disorder. Int J Dermatol. 2000;39:196–200
  41. Wahid Z, Kanjee A. Cutaneous manifestations of diabetes mellitus. J Pak Med Assoc. 1998;48:304–305
  42. Aye M, Masson EA. Dermatological care of the diabetic foot. Am J Clin Dermatol. 2002;3:463–474
  43. Huntley AC. Cutaneous manifestations of diabetes mellitus. Dermatol Clin. 1989;7:531–546
  44. Darmstadt GL, Yokel BK, Horn TD. Treatment of acanthosis nigricans with tretinoin. Arch Dermatol. 1991;127:1139
  45. Katz RA:. Treatment of acanthosis nigricans with oral isotretinoin. Arch Dermatol. 1980;116:110
  46. Noz KC, et al. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol. 1993;18:78
  47. Tidman M. Management of necrobiosis lipoidica. Clin Exp Dermatol. 2002;27:328
  48. Nguyen K, Washenik K, Shupak J. Necrobiosis lipoidica diabeticorum treated with chloroquine. J Am Acad Dermatol. 2002;46(2 Suppl Case Reports):S34–S36
  49. Stanway A, Rademaker M, Newman P. Healing of severe ulcerative necrobiosis lipoidica with cyclosporin. Australas J Dermatol. 2004;45:119–122
  50. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Dermatol Venereol. 1992;2:69
  51. Blume-Peytavi U, et al. Successful outcome of cryosurgery in patients with granuloma annulare. Br J Dermatol. 1994;130:494
  52. Saied N, Schwartz RA, Estes SA. Treatment of generalized annulare with dapsone. Arch Dermatol. 1980;116:1345
  53. Stables GI, et al. Scleredema associated with paraproteinemia treated by extracorporeal photopheresis. Br J Dermatol. 2000;142:781
  54. Lee MW, et al. Electron beam therapy in patients with scleredema. Acta Dermatol Venereol (Stockh). 2000;80:307
  55. Grundmann-Kolloman M, et al. Cream PUVA therapy for scleredema adultorum. Br J Dermatol. 2000;142:1058
  56. Ikeda Y, et al. Severe diabetic scleredema with extension to the extremities and effective treatment using prostaglandin E1. Int Med. 1998;37:861
  57. Mattheou-Vakali G, et al. Cyclosporin in scleredema. J Am Acad Dermatol. 1996;35:990
  58. Lieberman LS, Rosenbloom AL, Riley WJ, et al. Reduced skin thickness with pump administration of insulin. N Engl J Med. 1980;303:940–941
  59. Infante JR, Rosenbloom AL, Silverstein JH, et al. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. J Pediatr. 2001;138:33–37
  60. Eaton P, Sibbitt WL, Harsh A. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients. JAMA. 1985;253:1437–1440
  61. Eaton RP, Sibbitt WL, Shah VO, et al. A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes. J Diabetes Complications. 1998;12:34–38
  62. Sibbald RG, Tooth D, et al. Skin and diabetes. Endocrinol Metab Clin North Am. 1996;25:463–472
  63. Goodfield MJD, Millard LG. The skin in diabetes mellitus. Diabetologia. 1988;31:567–575
  64. Murphy DP, Tan JS, et al. Infectious complications in diabetic patients. Prim Care. 1981;8:695
  65. Harrison's Principles of Internal Medicine. 14th ed. McGraw-Hill Health Professional Division; 1998;
  66. Brook I, Frazier EH. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol. 1995;33:2382–2387
  67. Gorbach SL, Bartlett JG, et al. Infectious diseases. 2nd ed. Philadelphia: WB Saunders; 1998;
  68. Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg. 2000;87:718
  69. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis. 1995;1:69–78
  70. Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet. 1994;344:1111–1115
  71. Wong CH, Chang HC, Pasupathy S, et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003;85-A:1454–1460
  72. Doroghazi RM, Nadol JB, et al. Invasive external otitis. Isr J Med. 1981;71:603
  73. Rubin Grandis J, Branstetter BF, Yu VL. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis. 2004;4:34–39
  74. Rubin J, Yu VL. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med. 1988;85:391–398
  75. Barrow HN, Levenson MJ. Necrotizing ‘malignant’ external otitis caused by Staphylococcus epidermidis. Arch Otolaryngol Head Neck Surg. 1992;118:94–96
  76. Farr RC, Gardner G, Acker JD, et al. Blastomycotic cranial osteomyelitis. Am J Otol. 1992;13:582–586
  77. Scherbeuske JM, Winton GB, et al. Acute pseudomonas infection of the external ear (malignant external otitis). Dermatol Surg Oncol. 1988;14:165
  78. Munoz A, Martinez-Chamorro E. Necrotizing external otitis caused by Aspergillus fumigatus: computed tomography and high-resolution magnetic resonance imaging in an AIDS patient. J Laryngol Otol. 1998;112:98–102
  79. Gordon G, Giddings NA. Invasive otitis externa due to Aspergillus species: case report and review. Clin Infect Dis. 1994;19:866–870
  80. Bayardelle P, Jolivet-Granger M, Larochelle D. Staphylococcal malignant external otitis. CMAJ. 1982;126:155
  81. Coser PL, Stamm AE, Lobo RC, Pinto JA. Malignant external otitis in infants. Laryngoscope. 1980;90:312–316
  82. Lancaster J, Alderson DJ, McCormick M. Non-pseudomonal malignant otitis externa and jugular foramen syndrome secondary to cyclosporin-induced hypertrichosis in a diabetic renal transplant patient. J Laryngol Otol. 2000;114:366–369
  83. Scheinfeld NS. Obesity and dermatology. Clin Dermatol. 2004;22:303–309
  84. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;(10 Suppl 1):31–47
  85. Rashid M, Bari A, Majeed S, et al. Mucormycosis: a devastating fungal infection in diabetics. J Coll Phys Surg Pak. 2005;15:43–45
  86. McNulty JS. Rhinocerebral mucormycosis: predisposing factors. Laryngoscope. 1982;92(10 Pt 1):1140–1143
  87. Sandler R, Tallman CB, et al. Successfully treated rhinocerebral phycomycosis in well-controlled diabetes. N Engl J Med. 1971;285:1180
  88. De Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47:1843–1850
  89. Rajagopalan S. Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis. 2005;40:990–996[electronic publication 2005 Feb 24]
  90. Joachims HZ, Danino J, Raz R. Malignant external otitis: treatment with fluoroquinolones. Am J Otolaryngol. 1988;9:102–105
  91. Davis JC, Gates GA, Lerner C, et al. Adjuvant hyperbaric oxygen in malignant external otitis. Arch Otolaryngol Head Neck Surg. 1992;118:89–93
  92. Holdiness MR. Management of cutaneous erythrasma. Drugs. 2002;62:1131–1141
  93. Saltoglu N, Tasova Y, Zorludemir S, Dundar IH. Rhinocerebral zygomycosis treated with liposomal amphotericin B and surgery. Mycoses. 1998;41:45–49
  94. Bennett JE. Goodman and Gilman's The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006;
  95. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4:661–667
  96. Reeves W, Allen B, Tattersell R. Insulin induced lipoatrophy: evidence for an immune pathogenesis. BMJ. 1980;280:1500
  97. Young RJ, Hannan W, et al. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care. 1984;7:479
  98. Levandoski LA, White NH, Santiago JV. Localized skin reactions to insulin: insulin lipodystrophies and skin reactions to pumped subcutaneous insulin therapy. Diabetes Care. 1982;5:6
  99. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:361
  100. Thomson MICROMEDEX. All rights reserved. MICROMEDEX(R) Healthcare Series 126; 1974-2005.

PII: S0738-081X(06)00050-2

doi: 10.1016/j.clindermatol.2006.04.009

Clinics in Dermatology
Volume 24, Issue 4 , Pages 237-246 , July 2006

Article Tools

* Image Usage & Resolution